Ballicules.com

Carbachol

MIOSTAT

Carbachol ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Carbachol ballicule

What it isNon-selective cholinergic agonist resistant to cholinesterase; intraoperative miosis and glaucoma.

Why this oneIts resistance to hydrolysis gives a longer effect than acetylcholine in the eye.

What limits itSystemic absorption can cause sweating and abdominal cramps; use cautiously in patients with asthma, acute heart failure, or urinary obstruction.

Carbachol molecular structure (skeletal formula)
Molecular structure: Carbachol

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Miosis during ocular surgery; reduces IOP elevation in first 24 h after cataract surgeryAdultsNo more than 0.5 mL gently instilled into anterior chamber, single intraoperative doseSingle dose (miosis maximal within 2-5 min)0.5 mL

Renal Undefined

Hepatic Undefined

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy No adequate well-controlled studies; use only if potential benefit justifies fetal risk

Lactation Unknown whether excreted in breast milk; exercise caution in nursing women

Cost

Carbachol (MIOSTAT)
Strength#/mogeneric $/unitCostPlus
0.01 %solper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Carbachol is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Principal riskNicotinic as well as muscarinic activity, so systemic absorption causes broad cholinergic effect

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Sedation liability0 / 4
Direct muscarinic antagonism0 / 4

Open Carbachol in the interactive console ↗